Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
None
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients

therapy, herceptin targeted therapy or hormone therapy according to the NCCN (2011) guideline. The follow-up will be ten years after surgeries. The primary aim is to examine whether the docetaxel and

  • 0 views
  • 21 Jan, 2021
  • 14 locations
None
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …

docetaxel
stage iii breast cancer
fluorouracil
trastuzumab
tumor cells
  • 33 views
  • 07 Nov, 2020
  • 1 location
None
Efficacy and Safety Study of Trastuzumab Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer

To compare the efficacy in terms of the pathological complete response rate (pCR) to preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH)

erbb2
invasive breast cancer
carboplatin
trastuzumab
inflammatory breast cancer
  • 0 views
  • 08 Nov, 2020
  • 1 location
None
Evaluation of Tamoxifen's Efficacy for ER/PR Negative ER-beta Positive Operable Breast Cancer Patients

tumor's HER2 is positive, the patient can receive targeted therapy (Herceptin) combined with tamoxifen or placebo. The follow-up time will be eight years. The aim of this trial is to evaluate the

erbb2
breast-conserving surgery
mastectomy
endocrine therapy
herceptin
  • 30 views
  • 03 Feb, 2021
  • 17 locations
None
Pre Operative Trastuzumab in Operable Breast Cancer

single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute intravenous infusion in 250 ml of normal saline, in the window period of 10-15 4 to 14 days (both days inclusive) prior

trastuzumab
tumor cells
progesterone
gilbert's syndrome
endocrine therapy
  • 71 views
  • 26 Jan, 2021
  • 1 location
None
Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

RATIONALE: Zoledronic acid may help decrease the risk of broken bones, bone pain, and other symptoms caused by bone metastases. It may also help patients live more comfortably. PURPOSE: This randomized clinical trial is studying different schedules of zoledronic acid to compare how well they work in treating patients with …

bone metastases
bisphosphonate
zoledronic acid
bone pain
breast cancer
  • 124 views
  • 07 Nov, 2020
  • 1 location
None
Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer

positive HER-2, additional Herceptin could improve the response further. In this study the efficacy of combined neoadjuvant therapy with or without Herceptin should be evaluated and the role in predicting

erbb2
trastuzumab
measurable disease
epirubicin
herceptin
  • 7 views
  • 21 Jan, 2021
  • 2 locations
None
Detect V / CHEVENDO (Chemo vs. Endo)

Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) plus Kisqali (ribociclib) in patients with HER2 positive and

trastuzumab
endocrine therapy
platelet count
vinorelbine
fulvestrant
  • 27 views
  • 23 Jan, 2021
  • 1 location
None
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

>Trastuzumab (Herceptin)

erbb2
her2/neu-positive breast cancer
immunohistochemistry
trastuzumab
herceptin
  • 2 views
  • 22 Apr, 2021
None
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: Group A: Trastuzumab (Herceptin

erbb2
breast adenocarcinoma
immunohistochemistry
trastuzumab
tumor cells
  • 18 views
  • 01 Sep, 2021
  • 15 locations